Agilent Technologies, Inc. (A) Bundle
A Brief History of Agilent Technologies, Inc. (A)
Company Founding and Spin-off
Agilent Technologies was spun off from Hewlett-Packard (HP) on November 18, 1999. Initial public offering (IPO) price was $24 per share.
Financial Performance
| Fiscal Year | Revenue | Net Income |
|---|---|---|
| 2023 | $5.71 billion | $1.26 billion |
| 2022 | $5.42 billion | $1.18 billion |
Business Segments
- Life Sciences and Diagnostics
- Applied Markets
- Semiconductor and Electronics
Stock Performance
NYSE ticker symbol: A. Market capitalization as of January 2024: $38.5 billion. Stock price range (2023): $126.30 - $177.64.
Global Presence
Headquarters: Santa Clara, California. Employees: 17,000. Operations in 30+ countries.
Research and Development
Annual R&D investment: $1.1 billion in 2023. Patent portfolio: Over 2,000 active patents.
Key Acquisitions
- BioTek Instruments (2013): $375 million
- Varian, Inc. (2010): $1.5 billion
A Who Owns Agilent Technologies, Inc. (A)
Major Institutional Shareholders
| The Vanguard Group, Inc. | 9.76% |
| BlackRock Inc. | 8.34% |
| State Street Corporation | 5.62% |
| Capital World Investors | 4.97% |
| Dodge & Cox | 4.23% |
Top Insider Ownership
- Michael R. McMullen (Executive Chairman): 0.14%
- Padraig McDonnell (Chief Financial Officer): 0.05%
- Jacob Thaysen (President and CEO): 0.12%
Ownership Distribution
Public Float: 94.38%
Institutional Investors: 89.76%
Ownership Percentages by Investor Type
| Mutual Funds | 43.52% |
| ETFs | 22.14% |
| Individual Investors | 10.62% |
| Other Institutional Investors | 15.48% |
Agilent Technologies, Inc. (A) Mission Statement
Company Overview
Agilent Technologies, Inc. headquartered in Santa Clara, California, reported annual revenue of $5.98 billion for fiscal year 2023. Founded in 1999 as a spin-off from Hewlett-Packard, the company operates in three primary segments.
| Segment | 2023 Revenue | Primary Focus |
|---|---|---|
| Life Sciences & Diagnostics | $3.42 billion | Pharmaceutical research and clinical diagnostics |
| Semiconductor | $1.87 billion | Electronic design and semiconductor testing |
| Cellular Analysis | $690 million | Advanced cellular research technologies |
Mission Statement Components
Agilent's mission focuses on advancing scientific research and technological innovation across multiple industries.
- Develop cutting-edge measurement and analytical technologies
- Support scientific discovery in pharmaceuticals, healthcare, and electronics
- Provide high-precision instrumentation and solutions
Strategic Priorities
The company maintains a strong commitment to research and development, investing $1.14 billion in R&D during 2023, representing 19.1% of total revenue.
| R&D Investment | Percentage of Revenue | Global Patent Portfolio |
|---|---|---|
| $1.14 billion | 19.1% | 4,872 active patents |
Market Presence
Agilent operates in more than 110 countries, with approximately 17,400 employees worldwide as of 2023.
- Market capitalization: $41.3 billion
- Stock ticker: NYSE: A
- Global customer base across scientific research, medical, industrial sectors
How Agilent Technologies, Inc. (A) Works
Company Overview
Agilent Technologies, Inc. is a global technology company headquartered in Santa Clara, California. As of Q4 2023, the company reported annual revenue of $5.68 billion.
Business Segments
| Segment | Revenue (2023) | Key Products |
|---|---|---|
| Life Sciences & Diagnostics | $3.2 billion | Analytical instruments, genomic solutions |
| Applied and Semiconductor Markets | $2.1 billion | Electronic design automation, semiconductor testing |
| Diagnostics and Genomics | $370 million | Clinical diagnostics, genomic solutions |
Financial Performance
In 2023, Agilent reported:
- Gross margin: 62.4%
- Operating margin: 24.1%
- Net income: $1.29 billion
- Cash from operations: $1.52 billion
Global Presence
Agilent operates in more than 30 countries with approximately 17,000 employees worldwide.
Research and Development
R&D investment in 2023 was $812 million, representing 14.3% of total revenue.
Key Markets
- Pharmaceutical and biotechnology
- Academic research
- Government agencies
- Semiconductor industry
- Chemical and energy sectors
Stock Performance
As of January 2024, Agilent (NYSE: A) traded at approximately $106 per share, with a market capitalization of $31.8 billion.
Product Portfolio
| Category | Product Types | Primary Applications |
|---|---|---|
| Analytical Instruments | Chromatography systems, spectrometers | Chemical analysis, research |
| Electronic Test Equipment | Signal analyzers, oscilloscopes | Semiconductor testing |
| Life Science Solutions | Genomic sequencing tools | Medical research, diagnostics |
How Agilent Technologies, Inc. (A) Makes Money
Revenue Breakdown
Agilent Technologies, Inc. reported total revenue of $5.68 billion for the fiscal year 2023.
| Business Segment | Revenue (2023) | Percentage |
|---|---|---|
| Life Sciences and Applied Markets | $2.12 billion | 37.3% |
| Diagnostics and Genomics | $1.47 billion | 25.9% |
| Electronic and Semiconductor Test | $2.09 billion | 36.8% |
Product Categories
- Laboratory Instruments
- Diagnostic Solutions
- Semiconductor Test Equipment
- Chemical Analysis Instruments
Geographic Revenue Distribution
| Region | Revenue (2023) | Percentage |
|---|---|---|
| United States | $2.41 billion | 42.4% |
| Europe | $1.14 billion | 20.1% |
| China | $0.87 billion | 15.3% |
| Other Regions | $1.26 billion | 22.2% |
Key Financial Metrics
- Gross Margin: 62.1%
- Operating Income: $1.47 billion
- Net Income: $1.12 billion
- Research and Development Spending: $743 million
Customer Segments
Agilent serves multiple industries including:
- Pharmaceutical Companies
- Biotechnology Firms
- Chemical Manufacturers
- Academic Research Institutions
- Semiconductor Manufacturers
Pricing Strategy
Average selling prices for key product lines range from $50,000 to $500,000 depending on complexity and technological sophistication.
Agilent Technologies, Inc. (A) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.